Update on Cutaneous Manifestations of Infectious Diseases

Medical Clinics of North America

Volumn 93, Issue 6, 2009, Pages 1283-1290

  Elston, Dirk M ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

Chikungunya; Fungal; Monkey pox; MRSA; Mycobacteria; Staphylococcus

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTOBIPROLE MEDOCARIL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; ETHAMBUTOL; INFLIXIMAB; ITRACONAZOLE; LINEZOLID; MEROPENEM; MINOCYCLINE; PANIPENEM; PSEUDOMONIC ACID; RETAPAMULIN; RIFAMPICIN; STREPTOGRAMIN; SULTAMICILLIN; TEA TREE OIL; TELAVANCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BITE; DRUG TREATMENT FAILURE; HISTOPATHOLOGY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONKEYPOX; MORTALITY; MYCOBACTERIOSIS; MYCOSIS; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; VIRUS INFECTION;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; HUMANS; MYCOSES; SKIN DISEASES; VIRUS DISEASES;

EID: 70449673119     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2009.08.009     Document Type: Review

References (67)

1. Wilson M.E. The traveler and emerging infections: sentinel, courier, transmitter. J Appl Microbiol 94 Suppl (2003) 1S-11S
2. Shorr A.F. Epidemiology and economic impact of methicillin-resistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics 25 9 (2007) 751-768
3. Hoshino C., Satoh N., Sugawara S., et al. Community-acquired Staphylococcus aureus pneumonia accompanied by rapidly progressive glomerulonephritis and hemophagocytic syndrome. Intern Med 46 13 (2007) 1047-1053
4. Nourse C., Starr M., and Munckhof W. Community-acquired methicillin-resistant Staphylococcus aureus causes severe disseminated infection and deep venous thrombosis in children: literature review and recommendations for management. J Paediatr Child Health 43 (2007) 656-661
5. van Duijkeren E., Ikawaty R., Broekhuizen-Stins M.J., et al. Transmission of methicillin-resistant Staphylococcus aureus strains between different kinds of pig farms. Vet Microbiol 126 (2008) 383-389
6. Rajendran P.M., Young D., Maurer T., et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 51 (2007) 4044-4048
7. Fridkin S.K., Hageman J.C., Morrison M., et al. Active bacterial core surveillance program of the emerging infections program network. methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352 14 (2005) 1436-1444
8. Lee M.C., Rios A.M., Aten M.F., et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 23 2 (2004) 123-127
9. Young D.M., Harris H.W., Charlebois E.D., et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 139 9 (2004) 947-951
10. Ellis M.W., Griffith M.E., Dooley D.P., et al. Targeted intranasal mupirocin to prevent community-associated methicillin-resistant Staphylococcus aureus colonization and infection in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 51 (2007) 3591-3598
11. Seal J.B., Moreira B., Bethel C.D., et al. Antimicrobial resistance in Staphylococcus aureus at the University of Chicago Hospitals: a 15-year longitudinal assessment in a large university-based hospital. Infect Control Hosp Epidemiol 24 6 (2003) 403-408
12. Tsuji B.T., Rybak M.J., Cheung C.M., et al. Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. Diagn Microbiol Infect Dis 58 1 (2007) 41-47
13. Moore Z.S., Jerris R.C., and Hilinski J.A. High prevalence of inducible clindamycin resistance among Staphylococcus aureus isolates from patients with cystic fibrosis. J Cyst Fibros 7 (2008) 206-209
14. Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA. J Infect Chemother 13 3 (2007) 141-146
15. Marangon F.B., Miller D., Muallem M.S., et al. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol 137 3 (2004) 453-458
16. Horii T., Suzuki Y., Monji A., et al. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis 46 2 (2003) 139-145
17. Stein G.E., Schooley S., Peloquin C.A., et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 60 (2007) 819-823
18. Machado A.R., Arns Cda C., Follador W., et al. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Braz J Infect Dis 9 3 (2005) 191-200
19. Weigelt J., Itani K., Stevens D., et al., Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 6 (2005) 2260-2266
20. Sharpe J.N., Shively E.H., and Polk Jr. H.C. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 189 4 (2005) 425-428
21. Li J.Z., Willke R.J., Rittenhouse B.E., et al. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant Staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) 4 1 (2003) 57-70
22. Lin D.F., Zhang Y.Y., Wu J.F., et al. Linezolid for the treatment of infections caused by gram-positive pathogens in China. Int J Antimicrob Agents 32 (2008) 241-249
23. Cunha B.A. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 11 Suppl 4 (2005) 33-42
24. Tally F.P., Zeckel M., Wasilewski M.M., et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs 8 8 (1999) 1223-1238
25. Hsueh P.R., Chen W.H., Teng L.J., et al. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 26 1 (2005) 43-49
26. LaPlante K.L., and Rybak M.J. Daptomycin - a novel antibiotic against Gram-positive pathogens. Expert Opin Pharmacother 5 11 (2004) 2321-2331
27. Bennett J.W., Murray C.K., Holmes R.L., et al. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 60 4 (2008) 437-440
28. Mangili A., Bica I., Snydman D.R., et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40 7 (2005) 1058-1060
29. Hayden M.K., Rezai K., Hayes R.A., et al. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43 10 (2005) 5285-5287
30. Fritsche T.R., Sader H.S., Stilwell M.G., et al. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn Microbiol Infect Dis 52 3 (2005) 195-201
31. Bosó-Ribelles V., Romá-Sánchez E., Carmena J., et al. Tigecycline: a new treatment choice against Acinetobacter baumannii. Recent Pat AntiInfect Drug Discov 3 2 (2008) 117-122
32. Luh K.T., Hsueh P.R., Teng L.J., et al. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 44 12 (2000) 3374-3380
33. Saravolatz L.D., Pawlak J., and Johnson L.B. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 60 2 (2007) 406-409
34. Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41 10 (2005) 1407-1415
35. Imamura H., Ohtake N., Jona H., et al. Dicationic dithiocarbamate carbapenems with anti-MRSA activity. Bioorg Med Chem 9 6 (2001) 1571-1578
36. Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J Infect Chemother 11 5 (2005) 259-261
37. Bogdanovich T., Ednie L.M., Shapiro S., et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 49 10 (2005) 4210-4219
38. Vaudaux P., Gjinovci A., Bento M., et al. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49 9 (2005) 3789-3793
39. von Eiff C., Friedrich A.W., Becker K., et al. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob Agents Chemother 49 10 (2005) 4372-4374
40. Lee C.C., Tong K.L., Howe H.S., et al. Vibrio vulnificus infections: case reports and literature review. Ann Acad Med Singap 26 5 (1997) 705-712
41. Jain R., and Danziger L.H. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 38 9 (2004) 1449-1459
42. Okubo H., Iwamoto M., Yoshio T., et al. Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab. Mod Rheumatol 15 1 (2005) 62-64
43. Rallis E., Koumantaki-Mathioudaki E., Frangoulis E., et al. Severe sporotrichoid fish tank granuloma following infliximab therapy. Am J Clin Dermatol 8 6 (2007) 385-388
44. Salvana E.M., Cooper G.S., and Salata R.A. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect 55 6 (2007) 484-487
45. Sañudo A., Vallejo F., Sierra M., et al. Nontuberculous mycobacteria infection after mesotherapy: preliminary report of 15 cases. Int J Dermatol 46 6 (2007) 649-653
46. Redbord K.P., Shearer D.A., Gloster H., et al. Atypical Mycobacterium furunculosis occurring after pedicures. J Am Acad Dermatol 54 3 (2006) 520-524
47. Vugia D.J., Jang Y., Zizek C., et al. Mycobacteria in nail salon whirlpool footbaths, California. Emerg Infect Dis 11 4 (2005) 616-618
48. Cooksey R.C., de Waard J.H., Yakrus M.A., et al. Mycobacterium cosmeticum sp. nov., a novel rapidly growing species isolated from a cosmetic infection and from a nail salon. Int J Syst Evol Microbiol 54 Pt 6 (2004) 2385-2391
49. Gira A.K., Reisenauer A.H., Hammock L., et al. Furunculosis due to Mycobacterium mageritense associated with footbaths at a nail salon. J Clin Microbiol 42 4 (2004) 1813-1817
50. Giannella M., Pistella E., Perciaccante A., et al. Soft tissue infection caused by Mycobacterium chelonae following a liposculpture and lipofilling procedure. Ann Ital Med Int 20 4 (2005) 245-247
51. Chetchotisakd P., Kiertiburanakul S., Mootsikapun P., et al. Disseminated nontuberculous mycobacterial infection in patients who are not infected with HIV in Thailand. Clin Infect Dis 45 4 (2007) 421-427
52. Gomez M.P., Herrera-Leon L., Jimenez M.S., et al. Comparison of GenoType MTBC with RFLP-PCR and multiplex PCR to identify Mycobacterium tuberculosis complex species. Eur J Clin Microbiol Infect Dis 26 (2007) 63-66
53. Kobashi Y., Obase Y., Fukuda M., et al. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis 43 12 (2006) 1540-1546
54. Dodiuk-Gad R., Dyachenko P., Ziv M., et al. Nontuberculous mycobacterial infections of the skin: a retrospective study of 25 cases. J Am Acad Dermatol 57 3 (2007) 413-420
55. Petrini B. Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections. Eur J Clin Microbiol Infect Dis 25 (2006) 609-613
56. Fabroni C., Buggiani G., and Lotti T. Therapy of environmental mycobacterial infections. Dermatol Ther 21 3 (2008) 162-166
57. Cummins D.L., Delacerda D., and Tausk F.A. Mycobacterium marinum with different responses to second-generation tetracyclines. Int J Dermatol 44 6 (2005) 518-520
58. Petrini B. Mycobacterium abscessus: an emerging rapid-growing potential pathogen. APMIS 114 5 (2006) 319-328
59. Musa M.O., Al Eisa A., Halim M., et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol 108 3 (2000) 544-548
60. Anaissie E., Kantarjian H., Ro J., et al. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 67 2 (1988) 77-83
61. Martino P., Gastaldi R., Raccah R., et al. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 28 Suppl 1 (1994) 7-15
62. Cooper Jr. C.R., and McGinnis M.R. Pathology of Penicillium marneffei. An emerging acquired immunodeficiency syndrome-related pathogen. Arch Pathol Lab Med 121 8 (1997) 798-804
63. Adler A., Yaniv I., Samra Z., et al. Exserohilum: an emerging human pathogen. Eur J Clin Microbiol Infect Dis 25 4 (2006) 247-253
64. Ligon B.L. Monkeypox: a review of the history and emergence in the Western hemisphere. Semin Pediatr Infect Dis 15 4 (2004) 280-287
65. Kaur P., Ponniah M., Murhekar M.V., et al. Chikungunya outbreak, South India, 2006. Emerg Infect Dis 14 10 (2008) 1623-1625
66. Mishra K., and Rajawat V. Chikungunya-induced genital ulcers. Indian J Dermatol Venereol Leprol 74 4 (2008) 383-384
67. Economopoulou A., Dominguez M., Helynck B., et al. Atypical chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Réunion. Epidemiol Infect 137 4 (2009) 534-541